BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) gapped up before the market opened on Friday . The stock had previously closed at $4.96, but opened at $5.03. BioCryst Pharmaceuticals shares last traded at $5.33, with a volume of 1,666,041 shares trading hands.

BCRX has been the subject of several research analyst reports. Zacks Investment Research lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 9th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, May 9th. Jefferies Group upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Wednesday, June 1st. FBR & Co reiterated a “buy” rating and set a $6.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, July 6th. Finally, JMP Securities downgraded BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $8.22.

The stock’s market capitalization is $371.45 million. The firm has a 50-day moving average of $3.41 and a 200-day moving average of $3.23.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.04. The company earned $4.80 million during the quarter, compared to the consensus estimate of $3.92 million. The company’s revenue was down 81.4% compared to the same quarter last year. During the same period last year, the firm posted $0.06 earnings per share. Analysts forecast that BioCryst Pharmaceuticals Inc. will post ($1.03) earnings per share for the current fiscal year.

In other BioCryst Pharmaceuticals news, insider Thomas R. Staab II sold 14,577 shares of the business’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $4.43, for a total value of $64,576.11. Following the sale, the insider now directly owns 130,051 shares of the company’s stock, valued at $576,125.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

A hedge fund recently raised its stake in BioCryst Pharmaceuticals stock. Morgan Stanley increased its stake in BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) by 13.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 103,804 shares of the biotechnology company’s stock after buying an additional 12,646 shares during the period. Morgan Stanley owned about 0.14% of BioCryst Pharmaceuticals worth $1,071,000 as of its most recent SEC filing.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.